Share Email Print

Proceedings Paper

Transmyocardial revascularization by a 1000-watt CO2 laser: sole therapy
Author(s): John R. Crew M.D.; Marilyn Dean; Reinold Jones M.D.; John C. Fisher
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The concept of transmyocardial revascularization (TMR) providing blood flow to the left heart muscle based on the reptilian heart model has now been extended from an adjunctive procedure with coronary artery bypass to sole therapy. At Seton Hospital and Medical Center TMR is now being performed for the first time in clinical trials with patients who have no other mechanism of perfusion and a history of either failed PTCA or coronary artery bypass, with angina already under maximum medical therapy with a demonstrable ischemic muscle target. Longevity and reperfusion by tomographic thallium of these laser-drilled holes has been previously demonstrated but effectiveness of these channels for primary perfusion (sole therapy) apart from normal coronary bypass collateral supply is under investigation. Phase I of the FDA study has been completed with 15 cases and now Phase II includes three other beta test sites along with alternative therapy in marginal cases as the investigational format for the next 50 cases. More than 2 year followup in the first 15 cases is presented.

Paper Details

Date Published: 28 May 1993
PDF: 1 pages
Proc. SPIE 1879, Lasers in Urology, Gynecology, and General Surgery, (28 May 1993); doi: 10.1117/12.146242
Show Author Affiliations
John R. Crew M.D., Seaton Medical Ctr. (United States)
Marilyn Dean, Seaton Medical Ctr. (United States)
Reinold Jones M.D., Seaton Medical Ctr. (United States)
John C. Fisher, Surgical Consultant (United States)

Published in SPIE Proceedings Vol. 1879:
Lasers in Urology, Gynecology, and General Surgery
Christopher J. Daly M.D.; Warren S. Grundfest M.D.; Douglas E. Johnson M.D.; Raymond J. Lanzafame M.D.; Rudolf W. Steiner; Yona Tadir M.D.; Graham M. Watson M.D., Editor(s)

© SPIE. Terms of Use
Back to Top